The $13 Billion Blind Spot: How a Calgary Biotech is Rewriting Wound Care

CALGARY, AB – September 16, 2026 — We often measure the structural integrity of our healthcare system by its response to high-profile diseases. We build specialized hospitals for oncology, coordinate national campaigns for cardiovascular health, and mobilize massive resources for infectious outbreaks. Yet, quietly eroding the foundation of our medical infrastructure is a crisis that receives a fraction of the institutional attention: chronic, non-healing wounds.

Today, that systemic blind spot is being forced into the spotlight. Megan Leslie and Julian Mulia, the Calgary-based co-founders of biotechnology firm NanoTess, have been named honourees in the prestigious 2026 Canada's Top 40 Under 40 awards. The recognition, managed by Caldwell and announced in the Financial Post, celebrates the rapid clinical adoption of their flagship medical device, NanoSALV Catalytic. But for those tracking the fault lines of our public health systems, this award signals something far more significant: a fundamental shift in how we manage a devastating and costly medical burden.

The Escalating Cost of Compromised Healing

To understand the magnitude of NanoTess's achievement, one must first confront the grim economics of wound care. In Canada, chronic wounds—ranging from diabetic foot ulcers to severe pressure injuries—consume an estimated $13.1 billion annually in direct health expenditures. To put that into perspective, this figure rivals the $14.2 billion the health system spends treating lung, breast, colorectal, and prostate cancers combined.

Despite this staggering cost, the infrastructure supporting wound care remains deeply fragmented. Point-prevalence audits reveal that one in six acute-care patients suffers from pressure injuries, while community nursing programs dedicate up to half of their total hours exclusively to changing and managing wound dressings. The human toll is equally severe; the vast majority of lower-limb amputations in Canada are preceded by an unhealed diabetic foot ulcer.

Julian Mulia, Co-Founder and Chief Scientific Officer of NanoTess, articulates the disparity perfectly. "Complex wounds are an escalating health crisis. Canada spends close to $13 billion every year on wound care, nearly as much as the health system spends on lung, breast, colorectal and prostate cancer combined. Yet, unlike cancer, we don't have dedicated wound-care hospitals, centres, or an equivalent national infrastructure built for these patients."

From Personal Grief to Systemic Intervention

The genesis of NanoTess is rooted in the very systemic failures it now seeks to correct. The company was founded in 2020 following a deeply personal tragedy. Mulia lost both of his parents to complications arising from non-healing wounds—a cascade of systemic infections that traditional medical interventions failed to arrest.

"We founded NanoTess in 2020 from a deeply personal place," Mulia states. "After losing both my parents to complications arising from non-healing wounds, our mission became clear: bring advanced catalytic technologies to the growing number of people living with compromised healing capacity."

Partnering with Megan Leslie, whose background in organizational design and workforce transformation provided the strategic scaffolding for the enterprise, Mulia set out to engineer a solution that bypassed the limitations of the traditional standard of care. They recognized that the prevailing medical approach was fundamentally defensive. For decades, the standard protocol for chronic wounds has relied heavily on antimicrobial silver ions or cadexomer iodine. These treatments are designed to kill bacteria and manage surface infection. However, they are non-selective, frequently proving toxic to the very host cells required to rebuild tissue.

"And the problem is not simply infection," Mulia explains. "Products that kill bacteria do not necessarily address why a wound has stopped healing. A clean wound can still be a chronic wound. That distinction matters, especially for seniors and other vulnerable patients who often assume that because a wound has been disinfected or covered, it will heal."

Catalytic Healing: A Biomimetic Paradigm Shift

The technological leap that propelled NanoTess from a Calgary startup to a national healthcare player is its Catalytic Treatment Matrix (CTM). Authorized by Health Canada in 2022 as a Class II Medical Device, NanoSALV Catalytic abandons the passive, defensive posture of traditional dressings. Instead, it utilizes biomimetic nanotechnology—specifically, solid-state composite structures of catalytic copper—to actively alter the wound's microenvironment.

Chronic wounds often stall in a hyper-oxidative, inflammatory state. The catalytic copper structures in NanoSALV function similarly to artificial enzymes, neutralizing destructive reactive oxygen species and catalyzing the chemical signals necessary for cellular proliferation. By stimulating vascular endothelial growth factor expression, the matrix kickstarts capillary formation and oxygen delivery to oxygen-starved tissues.

"This is why we developed a solution that is fundamentally different: a biomimetic technology designed to reactivate intrinsic healing," Mulia adds. "What we never imagined was how quickly that technology would be adopted, how far it would reach, and how many lives it would ultimately touch."

The clinical data supports this rapid adoption. In multi-centre trials conducted in Alberta, evaluating patients with high-complexity wounds that had been open for an average of over a year and a half, the introduction of NanoSALV Catalytic demonstrated a 57.6 percent net improvement in wound area reduction over the standard of care. Retrospective analyses further revealed an 81 percent complete wound closure rate within 16 weeks—a stark contrast to the 40 to 50 percent closure rates typically seen with legacy advanced dressings.

Bridging the Gap Between Innovation and Equity

True structural change in healthcare requires more than scientific breakthroughs; it demands policy integration and equitable access. Historically, securing public formulary listing for outpatient medical dressings in Canada has been a monumental hurdle, often leaving vulnerable patients to shoulder out-of-pocket retail costs. When patients cannot afford advanced dressings at home, they inevitably relapse, turning a manageable pharmacy expense into a catastrophic acute hospital admission.

As one reconstructive surgeon noted during the advocacy process, investing in active wound regeneration upfront prevents the catastrophic downstream costs of surgical readmissions. NanoTess has systematically dismantled these barriers by proving this exact economic reality to public payers. The company successfully secured public coverage through the Alberta Drug Benefit List in August 2025, ensuring access for seniors, low-income individuals, and palliative care patients. This was followed by integration into the Ontario Health at Home formulary in August 2026, empowering community care nurses to procure the treatment directly for in-home patient protocols.

Simultaneously, a landmark national distribution partnership executed earlier this year has made NanoSALV Catalytic orderable without a prescription in 14,000 pharmacies nationwide, while maintaining a footprint in 2,500 hospitals and healthcare facilities.

Megan Leslie, Co-Founder and CEO, views this policy and distribution infrastructure as the true measure of their success. "Our North Star is a world where healing is possible for everyone - regardless of where you live, your health, age, or circumstances. And we have made meaningful progress towards that goal, but the work is far from finished," she says.

As healthcare systems globally brace for the pressures of an aging population and rising rates of diabetes, the demand for scalable, cost-effective regenerative medicine will only intensify. The rise of NanoTess serves as a blueprint for how domestic innovation can alleviate severe systemic bottlenecks.

"Across Canada and beyond, significant barriers to equitable access remain," Leslie notes. "Through our products, distribution partners, clinical advocates, and our social enterprise, we remain committed to reducing the obstacles that stand between people and healing. We're proud of what we have achieved as a team, and excited for the milestones – and the impact – that are yet to come."

The recognition of Leslie and Mulia as Top 40 Under 40 honourees is a celebration of a uniquely Canadian biotech success story. But more importantly, it highlights a critical pivot in public health: the realization that repairing the structural integrity of our healthcare system begins with giving the body the biological and economic tools to repair itself.